ArticleFrontiers in endocrinology2026
Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As long-term survival rates improve among thyroid cancer patients, the metabolic consequences of thyroidectomy and thyroid hormone therapy have gained increasing importance. While these treatments are crucial for cancer management, their long-term effects on metabolic health remain inadequately understood. Methods: We conducted a retrospective, population-based cohort study utilizing nationwide data from the Korea National Health Insurance Service. We estimated the risk of incident metabolic abnormalities (i) among patients with TC who underwent thyroidectomy compared with matched individuals from the general population without TC, (ii) among TC patients according to thyroidectomy status, and (iii) among TC patients who underwent thyroidectomy, according to thyroid hormone therapy status. The incidence of obesity, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease (MASLD) within 5, 8, and 10 years was estimated using multivariable logistic regression models, adjusting for age, sex, household income, alcohol consumption, smoking status, and physical activity. Results: Thyroidectomy was associated with higher odds of multiple metabolic abnormalities compared with the matched general population without TC and to TC patients without thyroidectomy, with most associations evident from 5 years onward and some from 8 years. Among TC patients who underwent thyroidectomy, thyroid hormone therapy was significantly associated with metabolic abnormalities. In sex-stratified analyses, overall patterns were largely similar; however, MASLD was not significantly associated with thyroidectomy or thyroid hormone therapy in males. Conclusion: Thyroidectomy and thyroid hormone therapy are associated with incidence of metabolic abnormalities within 5, 8, or 10 years among thyroid cancer survivors. These findings support ongoing metabolic monitoring in thyroid cancer survivors and warrant further studies to determine whether individualized hormone management can reduce long-term metabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.